Liver disease progression after Hepatitis C Virus (HCV) eradication following direct-acting antiviral (DAA) treatment in the real-life setting according to Human Immunodeficiency Virus (HIV) coinfection was evaluated

Barbaro, Francesco

Biliotti, Elisa

Blanc, Pierluigi

Chemello, Liliana

Chessa, Luchino

Coco, Barbara

D'Ambrosio, Roberta

Federico, Alessandro

Ferrigno, Luigina

Filomia, Roberto

Gentile, Ivan

Iannone, Andrea

Ieluzzi, Donatella

Kondili, Loreta A

Massari, Marco

Migliorino, Guglielmo

Monti, Monica

Morisco, Filomena

Morsica, Giulia

Parruti, Giustino

Puoti, Massimo

Quaranta, Maria Giovanna

Rumi, Maria Grazia

Russo, Francesco Paolo

Santantonio, Teresa Antonia

Segala, D.

Verucchi, Gabriella

Vinci, Maria

Zuin, Massimo

English

Background: Liver disease progression after Hepatitis C Virus (HCV) eradication following direct-acting antiviral (DAA) treatment in the real-life setting according to Human Immunodeficiency Virus (HIV) coinfection was evaluated. Methods: Patients consecutively enrolled in PITER between April 2014 and June 2019 and with at least 12-weeks follow-up following treatment were analysed. Cox regression analysis were used to evaluate HIV coinfection and factors independently associated with liver disease outcomes following viral eradication in DAA treated patients with pre-treatment liver cirrhosis. Results: 93 HIV/HCV coinfected and 1109 HCV monoinfected patients were evaluated during a median follow-up of 26.7 (range 6–44.6) and 24.6 (range 6.8–47.3) months, respectively. No difference in the cumulative HCC incidence and hepatic decompensation was observed between coinfected and monoinfected patients. Age (Hazard Ratio [HR] = 1.08; 95% CI 1.04–1.13), male sex (HR = 2.76; 95% CI 1.28–5.96), lower albumin levels (HR = 3.94; 95% CI 1.81–8.58), genotype 3 (HR = 5.05; 95% CI 1.75–14.57) and serum anti-HBc positivity (HR = 1.99, 95% CI 1.01–3.95) were independently associated with HCC incidence. Older age (HR = 1.03; 95% CI 1.00–1.07), male sex (HR = 2.13; 95% CI 1.06–4.26) and lower albumin levels (HR = 3.75; 95% CI 1.89–7.46) were independently associated with the appearance of a decompensating event after viral eradication. Conclusion: Different demographic, clinical and genotype distribution between HIV coinfected vs those monoinfected, was observed in a representative cohort of HCV infected patients in Italy. Once liver cirrhosis is established the disease progression is decreased, but still persists regardless of viral eradication in both coinfected and monoinfected patients. In patients with cirrhosis, HIV coinfection was not associated with a higher probability of liver complications, after viral eradication

Quaranta M. G.

Ferrigno L.

Monti M.

Filomia R.

Biliotti E.

Iannone A.

Migliorino G.

Coco B.

Morisco F.

Vinci M.

D'Ambrosio R.

Chemello L.

Massari M.

Ieluzzi D.

Russo F. P.

Blanc P.

Verucchi G.

Puoti M.

Rumi M. G.

Barbaro F.

Santantonio T. A.

Federico A.

Chessa L.

Gentile I.

Zuin M.

Parruti G.

Morsica G.

Kondili L. A.

Archivio della ricerca - Università degli studi di Napoli Federico II

Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort

Segala D.

Archivio istituzionale della ricerca - Università di Ferrara

Maria Giovanna Quaranta

Luigina Ferrigno

Monica Monti

Roberto Filomia

Elisa Biliotti

Andrea Iannone

Guglielmo Migliorino

Barbara Coco

Filomena Morisco

Maria Vinci

Roberta D’Ambrosio

Liliana Chemello

Marco Massari

Donatella Ieluzzi

Francesco Paolo Russo

Pierluigi Blanc

Gabriella Verucchi

Massimo Puoti

Maria Grazia Rumi

Francesco Barbaro

Teresa Antonia Santantonio

Alessandro Federico

Luchino Chessa

Ivan Gentile

Massimo Zuin

Giustino Parruti

Giulia Morsica

Loreta A. Kondili

on behalf of PITER Collaborating Group

Archivio Istituzionale della Ricerca- Università degli Studi di Foggia

Archivio istituzionale della ricerca - Alma Mater Studiorum Università di Bologna

Background Liver disease progression after Hepatitis C Virus (HCV) eradication following direct-acting antiviral (DAA)
treatment in the real-life setting according to Human Immunodefciency Virus (HIV) coinfection was evaluated.
Methods Patients consecutively enrolled in PITER between April 2014 and June 2019 and with at least 12-weeks follow-up
following treatment were analysed. Cox regression analysis were used to evaluate HIV coinfection and factors independently
associated with liver disease outcomes following viral eradication in DAA treated patients with pre-treatment liver cirrhosis.
Results 93 HIV/HCV coinfected and 1109 HCV monoinfected patients were evaluated during a median follow-up of 26.7
(range 6–44.6) and 24.6 (range 6.8–47.3) months, respectively. No diference in the cumulative HCC incidence and hepatic
decompensation was observed between coinfected and monoinfected patients. Age (Hazard Ratio [HR]=1.08; 95% CI
1.04–1.13), male sex (HR=2.76; 95% CI 1.28–5.96), lower albumin levels (HR=3.94; 95% CI 1.81–8.58), genotype 3
(HR=5.05; 95% CI 1.75–14.57) and serum anti-HBc positivity (HR=1.99, 95% CI 1.01–3.95) were independently associated with HCC incidence. Older age (HR=1.03; 95% CI 1.00–1.07), male sex (HR=2.13; 95% CI 1.06–4.26) and lower
albumin levels (HR=3.75; 95% CI 1.89–7.46) were independently associated with the appearance of a decompensating
event after viral eradication.
Conclusion Diferent demographic, clinical and genotype distribution between HIV coinfected vs those monoinfected, was
observed in a representative cohort of HCV infected patients in Italy. Once liver cirrhosis is established the disease progression is decreased, but still persists regardless of viral eradication in both coinfected and monoinfected patients. In patients
with cirrhosis, HIV coinfection was not associated with a higher probability of liver complications, after viral eradication

Archivio istituzionale della ricerca - Università di Cagliari

Archivio istituzionale della ricerca - Università di Padova

Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli"

https://iris.unife.it/bitstream/11392/2418647/2/Quaranta2020_Article_AdvancedLiverDiseaseOutcomesAf.pdf

Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort

Abstract

Similar works

Full text

Available Versions